Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor

(2021) Jiaxing Tang et al.   Frontiers in Pharmacology

Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs

(2021) Criselle D'Souza et al.   Frontiers in Immunology

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature

(2021) Guoxing Zhao et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CAR-T cell therapy: current limitations and potential strategies

(2021) Robert C. Sterner et al.   Blood Cancer Journal

Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

(2021) Lin Xia et al.   Cancer Immunology Research

Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors

(2021) Razan Mohty et al.   BONE MARROW TRANSPLANTATION

A histone deacetylase inhibitor, panobinostat, enhances chimeric receptor antigen T cell anti-tumor effect against pancreatic cancer

(2021) Aesha I. Ali et al.   CLINICAL CANCER RESEARCH

Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells

(2021) Zhigang Nian et al.   CLINICAL CANCER RESEARCH

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

(2021) Prasad S Adusumilli et al.   Cancer Discovery

Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy

(2021) Mingya Yang et al.   Frontiers in Immunology

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ

(2021) Sanjay Chandrasekaran et al.   Frontiers in Immunology

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

(2021) Bruno L. Cadilha et al.   Science Advances

T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

(2021) Stefanie Lesch et al.   Nature Biomedical Engineering

BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma

(2021) Lin Xia et al.   MOLECULAR THERAPY

Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy

(2021) Weizhen Li et al.   Frontiers in Pharmacology

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure

(2020) Jordan Gauthier et al.   BLOOD

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells

(2020) Connor J. Dwyer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

(2020) Tanja Stüber et al.   Journal for ImmunoTherapy of Cancer

Galunisertib enhances chimeric antigen receptor-modified T cell function

(2020) Zhixiong Wang et al.   EUROPEAN JOURNAL OF HISTOCHEMISTRY

Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients

(2020) Fuli Fan et al.   INTERNATIONAL JOURNAL OF CANCER

Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro

(2020) Meijing Liu et al.   CANCER SCIENCE

Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy

(2020) Eduardo Huarte et al.   CLINICAL CANCER RESEARCH

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome

(2020) Adam S. Kittai et al.   Blood Advances

Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells

(2020) Mingya Yang et al.   Frontiers in Immunology

IL-15-mediated reduction of mTORC1 activity preserves the stem cell memory phenotype of CAR-T cells and confers superior antitumor activity

(2019) Darya Alizadeh et al.   Cancer Immunology Research

Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients

(2019) Sophia Stock et al.   INTERNATIONAL JOURNAL OF CANCER

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

(2019) Paul J. Hampel et al.   LEUKEMIA & LYMPHOMA

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells

(2019) M. Feng et al.   Science Advances

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

(2019) Stefan Stoiber et al.   Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

(2019) Rosalie M. Sterner et al.   Jove-Journal of Visualized Experiments

CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models

(2019) Huizhong Li et al.   JOURNAL OF IMMUNOTHERAPY

Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide

(2019) Melissa Works et al.   MOLECULAR CANCER THERAPEUTICS

CAR‑T 19 combined with reduced‑dose PD‑1 blockade therapy for treatment of refractory follicular lymphoma: A case report

(2019) Jia Wang et al.   Oncology Letters

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

(2019) Yaqing Cao et al.   Frontiers in Oncology

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

(2019) Sattva S Neelapu et al.   BLOOD

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

(2019) Ran Reshef et al.   BLOOD

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy

(2019) Sophia Stock et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

(2018) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

A guide to manufacturing CAR T cell therapies

(2018) Philipp Vormittag et al.   CURRENT OPINION IN BIOTECHNOLOGY

PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells

(2018) Wenting Zheng et al.   LEUKEMIA

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

(2018) Theodoros Giavridis et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?

(2018) Maria C. Ramello et al.   PHARMACOLOGICAL RESEARCH

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

(2018) Amila Suraweera et al.   Frontiers in Oncology

Celecoxib in Cancer Therapy and Prevention – Review

(2018) Natalia Tolloczko - Iwaniuk et al.   CURRENT DRUG TARGETS

B cell adaptor for PI3-kinase (BCAP) modulates CD8+ effector and memory T cell differentiation

(2018) Mark D. Singh et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

(2018) Sarwish Rafiq et al.   NATURE BIOTECHNOLOGY

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

(2018) Rosalie M. Sterner et al.   BLOOD

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of PI3K signaling to improve CAR T cell function

(2018) Wenting Zheng et al.   Oncotarget

Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells

(2018) John P. Murad et al.   Frontiers in Immunology

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

Ibrutinib treatment improves T cell number and function in CLL patients

(2017) Meixiao Long et al.   JOURNAL OF CLINICAL INVESTIGATION

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells

(2017) Le Qin et al.   Journal of Hematology & Oncology

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells

(2017) Jacob S. Bowers et al.   Frontiers in Immunology

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy

(2017) Ryan Urak et al.   Journal for ImmunoTherapy of Cancer

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

(2016) Joseph A. Fraietta et al.   BLOOD

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma

(2016) M. Ruella et al.   CLINICAL CANCER RESEARCH

A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma

(2016) Drew C. Deniger et al.   CLINICAL CANCER RESEARCH

Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation

(2016) Maria-Luisa Schubert et al.   HUMAN GENE THERAPY

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

(2016) Frank A. Schildberg et al.   IMMUNITY

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

(2016) Yuki Kagoya et al.   JOURNAL OF CLINICAL INVESTIGATION

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

(2016) M Ruella et al.   LEUKEMIA

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Role of memory T cell subsets for adoptive immunotherapy

(2016) Dirk H. Busch et al.   SEMINARS IN IMMUNOLOGY

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

(2016) Eloah Rabello Suarez et al.   Oncotarget

Fine-tuning the CAR spacer improves T-cell potency

(2016) Norihiro Watanabe et al.   OncoImmunology

Lenalidomide enhances myeloma-specific T-cell responsesin vivoandin vitro

(2016) Isabelle Krämer et al.   OncoImmunology

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

(2016) Marco Ruella et al.   Computational and Structural Biotechnology Journal

Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses

(2015) S Kuramitsu et al.   CANCER GENE THERAPY

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

CAR therapy: the CD19 paradigm

(2015) Michel Sadelain   JOURNAL OF CLINICAL INVESTIGATION

BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro

(2015) Tessa Gargett et al.   JOURNAL OF IMMUNOTHERAPY

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice

(2015) Fei-Ting Hsu et al.   Oncotarget

Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells

(2015) Pavel Otáhal et al.   OncoImmunology

Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

(2014) J. G. Crompton et al.   CANCER RESEARCH

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

(2014) Dominique N Lisiero et al.   Journal for ImmunoTherapy of Cancer

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

(2013) S C H Karlsson et al.   CANCER GENE THERAPY

Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases

(2013) M. J. Riese et al.   CANCER RESEARCH

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA)

(2013) Ouaïssi Mehdi et al.   PANCREATOLOGY

Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity

(2013) L.-C. S. Wang et al.   Cancer Immunology Research

Role of PI3K/Akt signaling in memory CD8 T cell differentiation

(2013) Eui Ho Kim et al.   Frontiers in Immunology

Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment

(2013) Michael H Kershaw et al.   OncoImmunology

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

(2012) Timothy S. Fisher et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

(2012) Richard C. Koya et al.   CANCER RESEARCH

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

(2012) L Zhang et al.   GENE THERAPY

MAP kinase signaling and inhibition in melanoma

(2012) R J Sullivan et al.   ONCOGENE

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

(2011) Jerome B. Zeldis et al.   Annals of the New York Academy of Sciences

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment

(2011) Patrick A Ott et al.   Immunotherapy

Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation

(2011) J M McDaniel et al.   LEUKEMIA

Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination

(2011) Leslie E Huye et al.   MOLECULAR THERAPY

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients

(2010) Ingrid M.E. Desar et al.   INTERNATIONAL JOURNAL OF CANCER

The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3  Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex

(2010) J. S. Bridgeman et al.   JOURNAL OF IMMUNOLOGY

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms

(2010) Jiali Sun et al.   MOLECULAR THERAPY

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Pharmacologic Induction of CD8+ T Cell Memory: Better Living Through Chemistry

(2009) L. Gattinoni et al.   Science Translational Medicine

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor

(2008) Aaron E. Foster et al.   JOURNAL OF IMMUNOTHERAPY